Related Experiment Video
Updated: Nov 29, 2025
03:45
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
4.0K
Hypertrophic Cardiomyopathy in Pregnancy
1Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan School of Medicine, 1500 East Medical Center Drive, CVC Suite 2364, Ann Arbor, MI 48109-5853, USA.
Cardiology Clinics
|November 23, 2020
Summary
Hypertrophic cardiomyopathy (HCM) in women of childbearing age generally has favorable maternal and fetal outcomes. Genetic counseling and pre-pregnancy risk assessment are crucial for optimal management and monitoring during pregnancy.
Area of Science:
- Cardiology
- Genetics
- Reproductive Medicine
Background:
- Hypertrophic cardiomyopathy (HCM) is a primary genetic heart condition with significant heterogeneity.
- Increasingly diagnosed in women of reproductive age through advanced screening methods.
Purpose of the Study:
- To evaluate maternal and fetal outcomes in women with HCM during pregnancy.
- To outline recommended clinical management and risk stratification strategies.
Main Methods:
- Review of clinical data and outcomes for pregnant women with HCM.
- Emphasis on echocardiography, genetic screening, and clinical evaluations throughout gestation.
Main Results:
- Maternal and fetal outcomes for women with HCM are generally favorable.
- Most women experience moderate morbidity, requiring trimester evaluations and vaginal delivery.
- Symptomatic women or those with significant left ventricular outflow obstruction/arrhythmias face higher risks.
Conclusions:
- Pre-pregnancy evaluation and risk assessment are essential for managing HCM in pregnancy.
- Regular monitoring, including echocardiography, is vital, with more frequent assessments for high-risk individuals.
- Genetic counseling is recommended for women with HCM planning pregnancy.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
198
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
198
01:19Mitral Valve Prolapse III: Nursing Management
142
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
142
01:29Cardiomyopathy V: Interprofessional Care
147
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
147
01:30Cardiomyopathy II: Dilated Cardiomyopathy
229
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
229
01:25Cardiomyopathy I: Introduction and Classification
324
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
324
01:29Heart Failure II: Pathophysiology
377
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
377